A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621
- Citation:
- Lung Cancer vol 85 (2) 245-250
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 3
- Parents:
- 623
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- U10 CA180821, U10 CA180882
- Corr. Author:
- Authors:
- Julian R. Molina Nathan R. Foster Thanyanan Reungwetwattana Garth D. Nelson Andrew V. Grainger Preston D. Steen Philip J. Stella Randolph Marks John Wright Alex A. Adjei
- Networks:
- Study
- NCCTG-N0621
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Small cell lung cancer, saracatinib, C-Src